Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks | Circulation
Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gαi/o protein inhibitor - ScienceDirect
Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gαi/o protein inhibitor - ScienceDirect
Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice | Arteriosclerosis, Thrombosis, and Vascular Biology
Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice | Arteriosclerosis, Thrombosis, and Vascular Biology
Crystal Structure of the Human Cannabinoid Receptor CB1 - ScienceDirect
Rimonabant - Wikipedia
Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice | Arteriosclerosis, Thrombosis, and Vascular Biology
The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use -
Docking of rimonabant and THC to the CB1 receptor (a) Overlay of the... | Download Scientific Diagram
Blockade by the Cannabinoid CB1 Receptor Antagonist, Rimonabant (SR141716), of the Potentiation by Quinelorane of Food-Primed Reinstatement of Food-Seeking Behavior | Neuropsychopharmacology
Structure Activity of CB1 Cannabinoid Receptor Antagonists
Acomplia Active molecule : Rimonabant which is anorexigen inhibitor of type I cannabinoid receptors..., Stock Photo, Picture And Rights Managed Image. Pic. BSI-2009407 | agefotostock
Endocannabinoid System and Appetite – A Delicate Balance | Thorne
Structure Activity of CB1 Cannabinoid Receptor Antagonists
CB1 antagonists for obesity—what lessons have we learned from rimonabant? | Nature Reviews Endocrinology
Rimonabant: A Cautionary Tale for Targeting the Endocannabinoid System | Cannabis Sciences
Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice | Arteriosclerosis, Thrombosis, and Vascular Biology
The endocannabinoid system and its therapeutic exploitation | Nature Reviews Drug Discovery
Effects of pretreatment with the selective cannabinoid CB1-receptor... | Download Scientific Diagram
Novel Fubinaca/Rimonabant hybrids as endocannabinoid system modulators | SpringerLink
Acomplia (Rimonabant) - Investigational Agent for the Management of Obesity - Clinical Trials Arena
